NASDAQ
No price data available for this timeframe.
Apellis Pharmaceuticals, Inc. (APLS) has a consensus Buy rating from 25 analysts with an average price target of $33.40, representing -18.6% downside from the current price of $41.03.
| Date | Analyst | Firm | Target | Price | Upside |
|---|---|---|---|---|---|
| Apr 17, 2026 | Unknown | Wells Fargo | $41.00 | $40.87 | +0.32% |
| Jan 27, 2026 | Unknown | Barclays | $24.00 | $21.81 | +10.04% |
| Jan 20, 2026 | Unknown | Wells Fargo | $26.00 | $19.94 | +30.39% |
| Jan 13, 2026 | Unknown | Cantor Fitzgerald | $35.00 | $23.20 |
Sep 24, 2024 | Maintained | Wells Fargo | Equal Weight | Equal Weight |
Sep 23, 2024 | Maintained | Baird | Outperform | Outperform |
Sep 20, 2024 | Maintained | Needham | Buy | Buy |
Sep 20, 2024 | Maintained | Mizuho | Neutral | Neutral |
Sep 13, 2024 | Maintained | JP Morgan | Overweight | Overweight |
| Jan 12, 2026 | Unknown | Goldman Sachs | $19.00 | $23.20 | -18.10% |